María Auxiliadora Arrabal Vela1, Carlota Prado García Gijón2, María Pascual Martin2, Isabel Benet Giménez3, Vera Áreas Del Águila3, José Ramón Muñoz-Rodríguez4, Enrique Palomo Atance2. 1. Endocrinología Pediátrica, Servicio de Pediatría, Hospital General Universitario Ciudad Real, Ciudad Real, España. Electronic address: auxi.vela@hotmail.com. 2. Endocrinología Pediátrica, Servicio de Pediatría, Hospital General Universitario Ciudad Real, Ciudad Real, España. 3. Servicio Farmacia Hospitalaria, Hospital General Universitario Ciudad Real, Ciudad Real, España. 4. Unidad de Investigación Traslacional, Hospital General Universitario Ciudad Real, Ciudad Real, España.
Abstract
INTRODUCTION: Adherence to somatotropin treatment is associated with increased growth velocity and improved adult height. The purpose of this study is to determine the adherence of patients undergoing treatment with an electronic device and its relationship with different variables (age, gender, duration of treatment, diagnosis, height, and growth rate). MATERIAL AND METHODS: Descriptive, longitudinal and retrospective study of children less than 14 years of age undergoing treatment with somatotropin administered with the Easypod® electronic device in the Paediatric Endocrinology Outpatient Clinic of the General University Hospital of Ciudad Real, Spain. Adherence was monitored for 12 months and was defined according to the equation: (days administered at the prescribed dose / prescribed days)×100. The data analysis was performed using SPSS software. RESULTS: Data were collected from 30 patients, with a predominance of males (57%), a mean age of 6.09 years, with 51% of children less than 5 years old. The most common reasons for the treatment were: small for gestational age (55%) and growth hormone deficiency (38%). The mean duration of treatment was 4.3 years (3.6-5). A mean adherence of 92.3% (87.7-96.9) was observed, and there was a significant correlation with age (Pearson R = -0.384, P=.03), and duration of treatment (Pearson R = -0.537; P=.003). CONCLUSIONS: The adherence in our patients with electronic device is high (92.3%), and is inversely associated with age and duration. The use of electronic devices allows monitoring of therapeutic compliance, which affects the optimisation of treatment.
INTRODUCTION: Adherence to somatotropin treatment is associated with increased growth velocity and improved adult height. The purpose of this study is to determine the adherence of patients undergoing treatment with an electronic device and its relationship with different variables (age, gender, duration of treatment, diagnosis, height, and growth rate). MATERIAL AND METHODS: Descriptive, longitudinal and retrospective study of children less than 14 years of age undergoing treatment with somatotropin administered with the Easypod® electronic device in the Paediatric Endocrinology Outpatient Clinic of the General University Hospital of Ciudad Real, Spain. Adherence was monitored for 12 months and was defined according to the equation: (days administered at the prescribed dose / prescribed days)×100. The data analysis was performed using SPSS software. RESULTS: Data were collected from 30 patients, with a predominance of males (57%), a mean age of 6.09 years, with 51% of children less than 5 years old. The most common reasons for the treatment were: small for gestational age (55%) and growth hormone deficiency (38%). The mean duration of treatment was 4.3 years (3.6-5). A mean adherence of 92.3% (87.7-96.9) was observed, and there was a significant correlation with age (Pearson R = -0.384, P=.03), and duration of treatment (Pearson R = -0.537; P=.003). CONCLUSIONS: The adherence in our patients with electronic device is high (92.3%), and is inversely associated with age and duration. The use of electronic devices allows monitoring of therapeutic compliance, which affects the optimisation of treatment.
Authors: Roy Gomez; S Faisal Ahmed; Mohamad Maghnie; Dejun Li; Toshiaki Tanaka; Bradley S Miller Journal: Front Endocrinol (Lausanne) Date: 2022-03-01 Impact factor: 5.555
Authors: A Blanco-López; C Antillón-Ferreira; E Saavedra-Castillo; M Barrientos-Pérez; H Rivero-Escalante; O Flores-Caloca; R Calzada-León; C C Rosas-Guerra; E Koledova; E Chiquete; A Ayala-Estrada Journal: J Endocrinol Invest Date: 2020-04-01 Impact factor: 4.256